Bio-Rad quality controls, 9/17

September 2017—Bio-Rad Laboratories has added four analytes to the company’s Liquichek Tumor Marker Control. The updated control received FDA 510(k) clearance and the CE mark and is available for the immunoassay-based tumor marker testing market.

This enhanced Liquichek Tumor Marker Control features HE4 and HER2/neu. The other added analytes, ProGRP and SCC, are available only outside the U.S. Along with these analytes, Liquichek Tumor Marker Control offers low levels of prostate-specific antigen, high levels of cancer antigens, and the protein ferritin.

Bio-Rad announced the availability of Liquichek Serum Indices for monitoring preanalytical instrument detection of hemolyzed, icteric, and lipemic specimen interferences. Liquichek Serum Indices can be used as part of the preanalytical phase of a lab’s individualized quality control plan to help increase confidence in patient test results.

The company also launched a recombinant Luteinizing Hormone, which expands the company’s critical raw material offerings. The recombinant Luteinizing Hormone is part of the pituitary hormone product line engineered for a wide range of diagnostic uses. Luteinizing hormone, also known as lutropin and lutrophin, is primarily used to treat infertility, but it is also beneficial in the diagnosis of pituitary disorders and dysfunctions with the ovaries and testicles.

Bio-Rad, 510-741-7000